Tracking progress in universal influenza vaccine development

Julie Ostrowsky; Meredith Arpey; Kristine Moore; Michael Osterholm; Martin Friede; Jennifer Gordon; Deborah Higgins; Julia Molto-Lopez; Jonathan Seals; Joseph Bresee

doi:10.1016/j.coviro.2020.02.003

Tracking progress in universal influenza vaccine development

Julie Ostrowsky, Meredith Arpey, Kristine Moore, Michael Osterholm, Martin Friede, Jennifer Gordon, Deborah Higgins, Julia Molto-Lopez, Jonathan Seals, Joseph Bresee

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal protection against rapidly changing seasonal influenza viruses and a lack of protection against antigenically novel pandemic influenza. New technologies for developing influenza vaccines that induce more broadly protective and durable immunity are a growing area of research and focus on a variety of approaches, including targeting conserved antigens and stimulating cross-reactive T cell responses. This review highlights a new effort to track the development of universal influenza vaccine technologies. The Universal Influenza Vaccine Technology Landscape is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.

Original language	English (US)
Pages (from-to)	28-36
Number of pages	9
Journal	Current Opinion in Virology
Volume	40
DOIs	https://doi.org/10.1016/j.coviro.2020.02.003
State	Published - Feb 2020

Bibliographical note

Funding Information:
This work was supported by the Task Force for Global Health , under contract with the University of Minnesota . All authors participate in the Universal Influenza Vaccine Technology Landscape working group and all contributed to this review. The opinions expressed in this review do not necessarily reflect the views of the organizations with which the authors are affiliated.

Funding Information:
Neutrality and transparency are critical features of the landscape. The Task Force for Global Health, which established the Consortium with funding from the Bill and Melinda Gates Foundation, provides financial support to CIDRAP for the project. As an academic unit operating independently within the University of Minnesota, with no conflicts of interest regarding any influenza vaccine R&D activities or outcomes, CIDRAP serves as a neutral platform for gathering and analyzing influenza vaccine data for the landscape. In addition, a small working group was established for the project to provide critical review and subject-matter expertise in influenza vaccine R&D and vaccine database development. The working group includes representatives from the Task Force for Global Health, WHO, NIAID, the PATH Center for Vaccine Innovation and Access, the European Commission, and the US Biomedical Advanced Research and Development Authority (BARDA).

Publisher Copyright:
© 2020 Elsevier B.V.

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.coviro.2020.02.003

Find It

Find It at U of M Libraries

Cite this

@article{f62db39023e54e53a5dc034d2917a444,

title = "Tracking progress in universal influenza vaccine development",

abstract = "Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal protection against rapidly changing seasonal influenza viruses and a lack of protection against antigenically novel pandemic influenza. New technologies for developing influenza vaccines that induce more broadly protective and durable immunity are a growing area of research and focus on a variety of approaches, including targeting conserved antigens and stimulating cross-reactive T cell responses. This review highlights a new effort to track the development of universal influenza vaccine technologies. The Universal Influenza Vaccine Technology Landscape is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.",

author = "Julie Ostrowsky and Meredith Arpey and Kristine Moore and Michael Osterholm and Martin Friede and Jennifer Gordon and Deborah Higgins and Julia Molto-Lopez and Jonathan Seals and Joseph Bresee",

note = "Funding Information: This work was supported by the Task Force for Global Health , under contract with the University of Minnesota . All authors participate in the Universal Influenza Vaccine Technology Landscape working group and all contributed to this review. The opinions expressed in this review do not necessarily reflect the views of the organizations with which the authors are affiliated. Funding Information: Neutrality and transparency are critical features of the landscape. The Task Force for Global Health, which established the Consortium with funding from the Bill and Melinda Gates Foundation, provides financial support to CIDRAP for the project. As an academic unit operating independently within the University of Minnesota, with no conflicts of interest regarding any influenza vaccine R&D activities or outcomes, CIDRAP serves as a neutral platform for gathering and analyzing influenza vaccine data for the landscape. In addition, a small working group was established for the project to provide critical review and subject-matter expertise in influenza vaccine R&D and vaccine database development. The working group includes representatives from the Task Force for Global Health, WHO, NIAID, the PATH Center for Vaccine Innovation and Access, the European Commission, and the US Biomedical Advanced Research and Development Authority (BARDA). Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = feb,

doi = "10.1016/j.coviro.2020.02.003",

language = "English (US)",

volume = "40",

pages = "28--36",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Tracking progress in universal influenza vaccine development

AU - Ostrowsky, Julie

AU - Arpey, Meredith

AU - Moore, Kristine

AU - Osterholm, Michael

AU - Friede, Martin

AU - Gordon, Jennifer

AU - Higgins, Deborah

AU - Molto-Lopez, Julia

AU - Seals, Jonathan

AU - Bresee, Joseph

N1 - Funding Information: This work was supported by the Task Force for Global Health , under contract with the University of Minnesota . All authors participate in the Universal Influenza Vaccine Technology Landscape working group and all contributed to this review. The opinions expressed in this review do not necessarily reflect the views of the organizations with which the authors are affiliated. Funding Information: Neutrality and transparency are critical features of the landscape. The Task Force for Global Health, which established the Consortium with funding from the Bill and Melinda Gates Foundation, provides financial support to CIDRAP for the project. As an academic unit operating independently within the University of Minnesota, with no conflicts of interest regarding any influenza vaccine R&D activities or outcomes, CIDRAP serves as a neutral platform for gathering and analyzing influenza vaccine data for the landscape. In addition, a small working group was established for the project to provide critical review and subject-matter expertise in influenza vaccine R&D and vaccine database development. The working group includes representatives from the Task Force for Global Health, WHO, NIAID, the PATH Center for Vaccine Innovation and Access, the European Commission, and the US Biomedical Advanced Research and Development Authority (BARDA). Publisher Copyright: © 2020 Elsevier B.V.

PY - 2020/2

Y1 - 2020/2

N2 - Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal protection against rapidly changing seasonal influenza viruses and a lack of protection against antigenically novel pandemic influenza. New technologies for developing influenza vaccines that induce more broadly protective and durable immunity are a growing area of research and focus on a variety of approaches, including targeting conserved antigens and stimulating cross-reactive T cell responses. This review highlights a new effort to track the development of universal influenza vaccine technologies. The Universal Influenza Vaccine Technology Landscape is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.

AB - Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal protection against rapidly changing seasonal influenza viruses and a lack of protection against antigenically novel pandemic influenza. New technologies for developing influenza vaccines that induce more broadly protective and durable immunity are a growing area of research and focus on a variety of approaches, including targeting conserved antigens and stimulating cross-reactive T cell responses. This review highlights a new effort to track the development of universal influenza vaccine technologies. The Universal Influenza Vaccine Technology Landscape is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.

UR - http://www.scopus.com/inward/record.url?scp=85082952965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082952965&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2020.02.003

DO - 10.1016/j.coviro.2020.02.003

M3 - Review article

C2 - 32279026

AN - SCOPUS:85082952965

SN - 1879-6257

VL - 40

SP - 28

EP - 36

JO - Current Opinion in Virology

JF - Current Opinion in Virology

ER -

Tracking progress in universal influenza vaccine development

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this